FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on March 4, 2015, to select the influenza viruses for the composition of the influenza vaccine for the 2015-2016 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2014-2015 vaccines, and the availability of candidate strains and reagents.
The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2015-2016 influenza season contain the following:
- an A/California/7/2009 (H1N1)-like virus
- an A/Switzerland/9715293/2013 (H3N2)-like virus
- a B/Phuket/3073/2013-like virus
The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:
- a B/Brisbane/60/2008-like virus
.png)
No hay comentarios:
Publicar un comentario